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Ehrlich laid the foundation for the modern chemotherapy of
syphilis in 1907 with the synthesis of arsphenamine. His original
idea of effecting a total sterilization of the body tissues infected with
the Tr. pallidum by the intravenous injection of one or a few doses
of this drug in massive amounts was, unfortunately, soon shown to
be impracticable because of the toxic reactions obtained. In favor of
these massive spirocheticidal doses was adopted the present so-called
alternating block therapy method in which divided doses are spread
over a year or even years.
It is obvious that this method, spread over a year or years,
presents serious disadvantages, chief among which is the fact that
probably only 16 per cent or less of the patients treated by this
procedure receive adequate therapy as defined by the United States
Public Health Service.5 12 Indeed, Russell12 has estimated that in
the United States as a whole, 95 per cent of patients with early
syphilis received inadequate treatment.
The desirability of adequate treatment and the dangers of inade-
quate treatment have been stressedby the Cooperative Clinical Group
and ably presented by Moore.9 Moreover, Paget's recent presenta-
tion10 of the results attained in a group of early syphilitics treated
with the conventional form of therapy clearly demonstrates that
irregular or intermittent treatment leads to no better results than
are obtained with no treatment at all. Indeed, he goes so far as to
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suggest that if continuous treatment cannot be given, "no treatment
is the desideratum."
It is apparent, therefore, that a method which would greatly
shorten the duration of treatment and at the same time render non-
infectious and cure a large proportion of cases of early syphilis would
be of tremendous advantage not only to the infected cases but to
public health as well.
The possible answer to this problem is the development, nine
years ago, of the continuous-drip method of administering massive
doses of the arsenicals by Hyman and his associates Chargin and
Leifer in the clinics of the Mount Sinai Hospital. These workers
attempted the slow intravenous injection by continuous drip of 4
grams of Neoarsphenamine over a period of 5 days, reporting in
1935 upon a series of 25 cases2'6 and in 1939 upon an additional
86 cases.7 The clinical results were good. There was a rapid heal-
ing of primary and secondary lesions; dark-field examinations were
invariably negative within 48 hours; and it was found that 86 per
cent of the cases exhibited complete sero-reversal, usually within 10
to 16 weeks. Two patients became reinfected, 2 suffered a cutaneous
relapse, and 2 patients a serological relapse.
However, in view of one fatality due to hemorrhagic encephalitis
and to the relatively high incidence of serious reactions, particularly
cerebral symptoms, peripheral neuritis, jaundice, and exfoliative der-
matitis, the use of Neoarsphenamine was abandoned in favor of
Mapharsen (arsenoxide), a much less toxic but nevertheless thera-
peutically potent drug. Recent reports by Hyman and his group' 8
demonstrate a significantly lower toxicity with this drug. Cerebral
symptoms such as convulsions, disorientation, or hemorrhagic enceph-
alitis, though reduced in frequency and not associated with fatality,
were still present and offer, perhaps, the greatest drawback to the
use of massive arsenotherapy. There were, however, no fatalities
in a group of 275 patients treated with Mapharsen. Therapeutic
results, as judged by a one-to-two-year follow-up, were satisfactory.
Since January of 1940 this method of massive arsenotherapy by
the continuous intravenous drip, and employing Mapharsen as out-
lined below, has been in use at the New Haven Hospital for the
treatment of primary and secondary syphilis. In this report are
presented data concerning the procedure, toxicology, clinical observa-
tioIls, and therapeutic results already obtained with this modern form
of therapy in early syphilis. Subsequent reports in this series are
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concerned with the electrocardiographic changes4 and the complicat-
ing factor of pregnancy associated with or following therapy.15
Material and Technic
In this study 33 patients were given massive arsenotherapy.
Only patients in good physical condition were chosen for this study
and all were suffering from early syphilis. Three of these patients
(Cases 8, 12, and 13-R. R., M. F., and J. M.) received a second
course of therapy at 51, 40, and 19 weeks, respectively, following
the first "treatment course." The indications for re-treatment were
in order, serological relapse, serological fastness, and reinfection from
a known source with the production of a penile chancre.
Other pertinent data are listed in Table 1, where it can be seen
that approximately half of the patients were male and half were
female, with approximately the same proportion of white and black
TABLE I
CLINICAL DATA ON PATIENTS TREATED WITH MASSIVE ARSENOTHERAPY
33 Patients 36 "Treatment courses"*
Sex: Male ............................................ 5 (45 )
Female ......... ................................... 18 (55%b)
Color: White ....... 19 (58%5)
Black ... . . ........................................................................ 14 (42 )
Stage of syphilis:
Primary ....... 12 (33%o)
Secondary ....... 22 (61%)
Serological relapse ...... ( 3%o)
Serologically fast ...... ( 3%o)
Age Distribution:
Age: 15-19 20-24 25-29 30-34 35-39 40-44
Patients: 2 18 6 3 3 1
* 3 patients re-treated with massive arsenotherapy:
I- Reinfection, penile chancre.
- Serological relapse.
I - Sero-resistant.
races. Twelve of the 33 patients exhibited a primary lesion; 22
had, at the time of treatment or shortly before, manifestations of
secondary syphilis. The remaining 2 patients were numbered among
those who received re-treatment, in one instance due to a serologicalYALE JOURNAL OF BIOLOGY AND MEDICINE
relapse, in the other to serological fastness. The age distribution
was that ordinarily seen in early syphilis, the majority of patients
falling into the early adult group of 20 to 30 years of age.
No additional treatment prior to massive arsenotherapy was
administered except for that noted in Table 2. Eight patients
received one or two doses of bismuth subsalicylate in oil intramuscu-
TABLE 2
CASES RECEIVING ADDITIONAL TREATMENT PRIOR TO MASSIVE ARSENOTHERAPY
No. of No. of days before
Case Drug Dosage doses massive arsenotherapy
I -B. B. Bismuth subsalicylate 0.2 gm. 1 5
2-J. McC.
cc c 0.2 " 1 2
3-I.R. 0.2 " 1 2
4-E. M. 0.2 " 1 I
-L. C. 0.2 " I I
7-G.B. 0.2 " 2 1 and3
18-F. D. 0.2 " 1 5
23-E. S. 0.2 " 1 42
12-M. F.' Mapharsen 0.02 " 1 7
14-A. P. Neoarsphenamine 0.4 " 1 21
26-E. P. Mapharsen 0.02 cc 1 3
29-V. I.
cc 0.06 " 1 6
35-A. Fr.
(C 0.06 " 1 14
larly one to five days (in one instance 42 days) before treatment,
mainly with the idea of ascertaining if this would prevent a Herx-
heimer reaction. Five patients received an arsenical intravenously
prior to therapy, 2 of the injections having been given before the
patient was referred to the hospital. Two cases received 0.02 gm.
of Mapharsen; 2 cases received 0.06 gm. of Mapharsen; and 1 case
was given 0.4 gm. of Neoarsphenamine. These injections were
administered from 3 to 21 days before beginning the continuous drip.
No antisyphilitic therapy was given after the 5-day intravenous
drip except in 1 instance. This patient (Case 7-G. B.) spent from
the 5th to the 20th week in Pennsylvania following therapy and
while there was given by a physician a series of 10 simultaneous
intravenous and intramuscular injections. The authenticitv of the
patient's story could not be confirmed nor could the type of anti-
syphilitic drug be ascertained.
The details of dosage and administration of the continuous drip
336FIG. 1. Arrangement of apparatus as employed at the New Haven Hospital for massive
arsenotherapy by the continuous-drip method.
FIG. 2. An approved method for anchoring the intravenous needle. Note that the needle is
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of Mapharsen, as previously described by the Mount Sinai group,1 8
have been strictly adhered to, the only minor modification being in
regard to the type of intravenous set-up employed. As illustrated
in Fig. 1, the calibrated burette contains a solution of 5 per cent
glucose, in each 200 cc. of which are dissolved 20 mg. of Mapharsen.
This solution is administered daily for 5 days by the intravenous
route for a constant 12-hour period at the rate of 200 cc. of solution
per hour. We are in the habit of preparing this solution at 4-hour
intervals by dissolving the contents of two 0.04-gm. ampoules of
Mapharsen in 800 cc. of 5 per cent glucose. The treatment is
ordinarily begun at 8:00 o'clock in the morning and concluded by
8:00 o'clock at night.
With the procedure outlined above, the patient receives 0.24 gm.
of Mapharsen daily, or a total of 1.2 gm. for the 5-day period.
The method calls for excellent venepuncture technic. It is
important that the needle (20 gauge, 1>2" long, short bevel point)
be buried to the hilt and securely anchored as illustrated in Fig. 2,
so that the patient may move his arm at will without dislodging the
needle. Another important factor is the insertion of the needle in
the veins of the lower half of the forearm; again, so that the free
movement of the arm may be obtained. Each arm is used on alter-
nate days.
Patients received the routine hospital diet, which in most
instances was well taken except during the first day when the
majority vomited. For the greatest efficiency, it was found desirable
to have a special nurse assigned to one or more patients receiving the
drip in order to refill the gravity burette, regulate the rate of flow
of the Mapharsen solution, and to offer general nursing care. In
general, little, and at times no, discomfort was suffered by the
patient after the first day of the drip when the Herxheimer reaction
ordinarily occurs.
On admission, the patient underwent the following laboratory
examinations: blood count including differential and platelet count,
complete urine examination, chest x-ray, electrocardiogram, non-
protein nitrogen of the blood, and, in the first half of the series, a
liver function test and a phenolsulfonphthalein kidney-excretion test.
Since no abnormalities in the two latter tests could be detected at
the end of therapy, their routine performance was discontinued.
The blood count and urine examinations were repeated during and
after the course of therapy, and in most instances the non-protein
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nitrogen of the blood was checked following the full course of
therapy. The platelet count was checked one hour after beginning
therapy.7 Details concerning the conduct of theelectrocardiographic
examinations are reported in a subsequent paper.4
In practically all cases, lumbar puncture was performed either
before or immediately after continuous-drip therapy and, whenever
possible, repeat examination of the cerebrospinal fluid with cell count,
Pandy, colloidal gold, and Wassermann reaction was carried out
from the 3rd to the 6th month and at the end of the first year.
Dark-field examination of material from the primary lesion and
in some cases from secondary lesions was done. The standard Kahn
test and a modification of the Kolmer complement fixation (qualita-
tive) reaction, hereafter termed the Wassermanntest, were employed
as the methods of serological study.
Follow-up examinations with clinical and serological checks were
performed in the Out-patient Syphilis Clinic of the New Haven
Hospital.
Toxicology
Primary fever. The toxicological data are summarized in
Table 3. A primary fever of IO1.0° or higher was seen in 14 (39
TABLE 3
TOXIC REACTIONS IN PATIENTS TREATED WITH MASSIVE ARSENOTHERAPY
Reaction No. in 36 "Treatment courses"
Primary fever (T. 1010 or higher) .............................. 14 (39go%)
Secondary fever (T. 101° or higher) ............................ 10 (28%)
Toxicoderma ............. ........................... 7 (19%o)
Jaundice .......... ...............................1 ( 3%o)
Peripheral neuritis (with hypesthesia) ........................ 5 (14%)
cc cc (paresthesias only) .................... ...... 13 (36%o)
Nausea and vomiting .......................... .............. 29 (81 o)
Local thrombophlebitis ........................................8 (22%o)
Leukopenia (under 5000) ........................................ 2 ( 6 %)
Late secondary anemia ........................................ I I* (48 %)
Changes in the electrocardiogram .................................. Frequent
Cerebral symptoms ....................0....................
Hemorrhagic encephalitis ........................................0
Exfoliative dermatitis ..........................0..............
Fatality 0........................................
* Blood checked during follow-up period in 23 cases.MASSIVE ARSENOTHERAPY OF SYPHILIS
per cent) of the 36 "treatment courses" administered. Except for
5 patients in this group the temperature did not rise over 103.00 F.
This fever ordinarily consisted of a brisk rise in temperature within
from 6 to 10 hours after the treatment had been started on the first
day and was sometimes accompanied by a chill. The elevation may
continue for from 2 to 4 hours and then begins to abate, reaching
normal in another 2 to 6 hours despite continued therapy with
arsenic. This reaction is, of course, synonymous with the Herx-
heimer reaction, and discontinuance of therapy is not necessary when
it appears. In addition to this severe or moderately severe Herx-
heimer reaction, we have observed what could be termed a mild
Herxheimer reaction in another I1 cases (31 per cent). This was
characterized by fever below 101.00 F. with or without a rash,
malaise, or headache. Thus, approximately two-thirds of the
patients suffered either a mild or severe Herxheimer reaction.
Although this primary fever of 101.00, or higher, has no serious
connotation, we thought it to be of interest to attempt to prevent it
by the preliminary injection of a bismuth compound or an arsenical.
A glance at the material in Tables 2 and 4 suggests that there is no
TABLE 4
PREVENTION OF PRIMARY FEVER*
No. of Primary fever Primary fever
Preliminary treatment cases present absent
None ................................................ 23 11 (48go) 12(52%O)
Bismuth (intramus.) ........................ 8 3 (37%7°) 5 ( 63%)
Arsenical (intraven.) ........................ 5 0 5 ( I00%go)
*Fever of 101.00 F. or higher.
dear-cut evidence that bismuth is of any aid in preventing the
Herxheimer reaction, at least, if the bismuth is given within 5 days
of starting therapy. On the other hand, it is clearly evident that
in all 5 cases receiving an arsenical prior to massive arsenotherapy,
primary fever of 101.00 F., or higher, was not seen in a single
instance even though as little as 0.02 gm. of Mapharsen was given 3
days prior to the course of therapy. It is only fair to point out,
however, that in this particular case, as severe a Herxheimer reaction
as any we have ever seen developed 8 hours after the single 0.02
gm. injection of Mapharsen, with the fever reaching 103.20 F.
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Our experience has been similar in other cases of early syphilis
receiving the first single dose of an arsenical while under hospital
observation. It is clear, therefore, that the Herxheimer reaction is
not peculiar to massive arsenotherapy, but can be found with other
forms of therapy if the patient is observed.
Secondary fever. Secondary fever of 101.00 or higher was
found in 10 (28 per cent) of the cases, and in all but one instance
was less than 103.00 F. It usually lasted one or two days, but
twice it lasted for 3 days and once for 4 days. This fever appeared
between the 3rd and the 6th day, most often on the 5th day. In
an additional 10 cases (28 per cent) a low-grade fever of less than
101.00 F. was seen, beginning on the 4th, 5th, or 6th day and lasting
one or two days.
Toxicoderma. The secondary fever described above may appear
with a toxicoderma or the toxicoderma may appear without a febrile
reaction. In 7 cases such a toxicoderma was seen at the end of
therapy. In all but one instance it was associated with fever.
Although ordinarily of a maculo-papular type, rashes of erythe-
matous, macular, or urticarial varieties were seen. These rashes
were of an evanescent character, disappearing within 24 to 48 hours.
No eruption of an exfoliative nature was observed. It may be of
interest to comment upon the fact that while Case 8 (R. R.) devel-
oped a maculo-papular toxicoderma on the first course of therapy,
no eruption and, indeed, no reaction of any type was observed when
she was given a second treatment course of massive arsenotherapy
because of a serological relapse.
Jaundice. Although liver function (bromsulphalein excretion)
tests were carried out before and after therapy on approximately half
of the patients, and the icteric index was performed throughout
therapy in a few instances, no evidence of damage to the liver was
found in this particular group. In a case (35-A. Fr.) apart from
this group, however, jaundice developed on the 4th day and because
of the complicating factors the following history is related:
The patient, a 20-year-old negress, was admitted with a generalized
secondary syphilitic eruption, dark-field positive. She received an injection of
0.06 gm. of Mapharsen intravenously and was discharged the following day,
to be followed at frequent intervals with electrocardiograms. It may be noted
that she developed a Herxheimer reaction 3 hours after injection, with malaise,
vomiting, and fever of 103.0° F. Fourteen days after the initial treatment
she was re-admitted for massive arsenotherapy. On routine examination a
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temperature of 103.20 F. was found with a normal leukocyte count of 8,200
per cu. mm. Despite this fever there were no complaints and since it
appeared likely that this fever was that remaining from an "erythema of the
9th day,"1' treatment by means of the constant drip was started on the fol-
lowing morning, a procedure which appears in retrospect to have been unwise.
The temperature gradually declined, reaching practically normal by the 5th
day of therapy. Vomiting was troublesome throughout the course of therapy.
On the night of the 4th day of therapy, there was a suggestive icteric tint
to the sclerae. On the following morning, the 5th and final day of therapy,
jaundice of the sclerae was definite and the icteric index was 50. There
was no bile or urobilin in the urine. Treatment for the day was continued,
the patient thus receiving a full course of arsenical therapy. Two days later,
the icteric index had dropped to 40. There was a questionably faint positive
reaction for bile in the urine, and the non-protein nitrogen of the blood was
30 mg. per cent. Increase in liver dulness suggested that there had been a
slight enlargement of the liver. The patient was discharged the following
day. On the first follow-up visit, a week after therapy, there was no clinical
evidence of jaundice. The liver was not enlarged and the icteric index had
dropped to 15. However, the hemoglobin which had ranged between 67
and 78 per cent (15.4 gm. = 100 per cent) up to the time of discharge from
the hospital, now had fallen to 55 per cent with a red cell count of 2,500,000
per cu. mm. There was marked weakness, presumably due to the anemia.
Ferrous sulfate was administered, and a week later blood examination revealed
that there had been a rise to a red cell count of 3,100,000 and the hemo-
globin was 62 per cent. The icteric index was 10. However, despite a
definite improvement in her fatigue, she complained of numbness and tingling
of the right leg and on examination there was found a hypesthesia on the right.
Another week later, 3 weeks after therapy, the blood count had risen to
3,900,000 and the hemoglobin was 75 per cent. She now complained bitterly
of pain in both legs, especially severe when walking. There was a hypesthesia
of both lower extremities up to the knees with patchy areas of hyperesthesia in
this region. Thiamine chloride, 50 mg., was given subcutaneously and 15
mg. daily by mouth was prescribed. A week later, the pain was still severe
and because of weakness of the extensors of the right hand with hypesthesia,
together with weakness which had developed in the extensors of the right foot,
she was admitted to the hospital for observation. This is the patient's present
status.
It is evident that there are many complications in this case. This
patient developed jaundice (and presumably toxic hepatitis) during
therapy, this clearing without incident. Shortly after hospital dis-
charge, a severe anemia developed, this also clearing without inci-
dent. Three weeks after therapy a peripheral neuritis developed,
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at first sensory only, then involving the motor fibers to a minor
degree.
Peripheral neuritis. Peripheral neuritis, as evidenced by pares-
thesias in the lower extremities such as numbness and tingling, was
found in 18 (50 per cent) of the cases, usually at about the 2nd or
3rd week following therapy. In only 5 cases (14 per cent) was
hypesthesia present and except for the one case described above
(35-A. Fr.) was minimal, only a stocking hypesthesia of the feet
being usually observed. Indeed, the neuritis was ordinarily so mild
that only careful questioning elicited any complaints. The pares-
thesias lasted only for a day or two, the hypesthesias for about a
week. All cleared without residual signs or symptoms. Hyman
and his associates' have found that the use of vitamin B1 is valueless
in this condition, either as a prophylactic or therapeutic agent, when
associated with arsenotherapy.
No evidence of motor involvement was made out except for the
one case (35-A. Fr.) described above. It would appear reasonable
to conclude that this motor neuritis was due to the toxic effects of
arsenic. If this is correct, such a reaction would be unusual, since
it has not been described in reports from the Mount Sinai Clinic in
which Mapharsen was employed. It may be possible that the toxic
hepatitis prevented the satisfactory excretion of arsenic to some
degree, thus causing the blood concentration of arsenic to rise to
dangerously high levels.
Nausea and vomiting. Vomiting occurred at least one or more
times during therapy in 91 per cent of the patients and in two
TABLE 5
SEVERITY OF VOMITING IN PATIENTS TREATED WITH MASSIVE ARSENOTHERAPY
No. of times vomiting during treatment in 36 "Treatment courses"
at least I x 29 (81%)
at least 3 x 26 (72%)
at least 10 x - 14 (39%)
at least 20 x - 4 (1%go)
at least 50 x 2 (6%)
Male (16) Female (20)
at least 1 x 10 (62%o) 19 (95go)
at least 3 x - 7 (44%O) 19 (95%o)
at least 10 x - 2 (12go) 12 (60%7o)
at least 20 x 4 (20%o)
at least 50 x 2 (I0%o)
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instances the vomiting was so severe as to be recorded as occurring
50 or more times during the "treatment course." Full details are
given in Table 5, from which it appears that vomiting is decidedly
more severe in the female. If our data are analyzed according to
the number of days on which the patients vomit (Table 6), a similar
TABLE 6
SEVERITY OF VOMITING IN PATIENTS TREATED WITH MASSIVE ARSENOTHERAPY
Number of days vomiting during treatment in 36 "Treatment courses"
at least I day 29 (81%o)
at least 2 days - 16 (55%o)
at least 3 days - 12 (33%o)
at least 4 days - 7 (19%o)
at least 5 days - 4 (11%o)
at least 6 days 2 ( 6%o)
for 7 days - I ( 3%)
Male (16) Female (20)
at least I day - 10 (62go) 19 (95%o)
at least 2 days 2 (12%o) 14 (70%o)
at least 3 days 2 (12%o) 10 (50%o)
at least 4 days - 7 (35%o)
at least 5 days 4 (20%o)
at least 6 days 2 (10%o)
for 7 days - 1 (5%o)
discrepancy between male and female is again evident. The major-
ity of patients vomit for less than three days, and in most instances
the vomiting is most severe on the first day of therapy.
Nausea and vomiting seen with massive arsenotherapy are not
of serious import, though at times they may be extremely trouble-
some. We have not found any particular sedative that will control
the disturbance. Facilities for electrolyte study were not available,
but we rather suspect that electrolyte changes of an extensive nature
do not occur, since in three of the cases under study and in which
chloride determinations were carried out on the blood serum by one
of us at the end of therapy, the chloride values in m.eq. were 89.0,
95.0, and 99.5, the three patients vomiting 53, 19, and 12 times,
respectively, duringthe course oftherapy.
Local thrombophlebitis. Pain of a cramp-like nature in the arm
and forearm of the extremity being used for injection was seen in
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practically every case, though in most instances the pain was slight.
A moderately severe local thrombophlebitis of the veins of the fore-
arm was seen in 8 (22 per cent) cases, usually on the 4th or 5th
day of therapy. In one instance this reaction was severe with
marked pain, shaking chills, and a temperature of 104.0 to 105.00
for three days beginning on the 5th day of therapy. Recovery was
without incident.
In all instances of thrombosis, the vein re-canalized and could
be used for venepunctures within a month or two after treatment.
Leukopenia. A leukocyte count falling to less than 5,000 was
seen in two cases at the end of therapy or shortly thereafter. In
neither case was there a neutropenia and in both instances the leu-
kocytes returned to a normal level within 48 hours.
Late secondary anemia. In 23 patients the red cell count and
the hemoglobin concentration in the blood were observed during the
first month of the follow-up period. It was found that in 11 (48
per cent) of this group there was evidence of the development of a
secondary type of anemia in which the red cell count had dropped
by from 700,000 to 800,000 or more and the hemoglobin concen-
tration by 15 per cent or more. It is only fair to point out that
except for three cases (I1-B. B., 3-I. R., and 35-A. Fr.) in which
the initial hemoglobin concentration was in the neighborhood of 65
to 75 per cent and in which, with the drop, readings of 55 to 60
per cent were obtained, the anemia was not clinically significant. In
these particular instances, marked pallor and fatigue were evident.
It may be significant that all three were negresses.
The anemia usually reached its peak by the first or second week
following therapy. It is difficult to evaluate the effect of iron
therapy in these cases, though it would be our general clinical impres-
sion that regeneration of hemoglobin was not materially affected by
ferrous sulfate therapy, at least in the patients with a milder form
of anemia.
Electrocardiographic changes. Serial electrocardiograms obtained
before, during, and after massive arsenotherapy revealed significant
abnormalities of the T waves that developed in most of the cases
studied during the course of the treatment.13 The electrocardio-
graphic changes appeared to represent toxic arsenic effects of transient
and benign nature, the abnormalities disappearing during the follow-
up period. A detailed presentation of the electrocardiographic
studies appears in a subsequent paper of this series.4
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Other toxic reactions to arsphenamine. Other toxic reactions,
seen with arsenical therapy, such as convulsions, coma, hemorrhagic
encephalitis, and exfoliative dermatitis, were not seen in our partic-
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FIG. 3. Graphic illustration of the serological changes observed in the group of 36 "treatment
courses." In this chart the vertical double line represents the 5-day period of therapy and the
portion of the several horizontal columns to the left of this line indicates the status of the
serology before treatment; that portion to the right of the double line shows the serology after the
treatment. Under "Stage," P indicates primary syphilis; S, secondary syphilis; S.R., serological
relapse; and S.F. serologically fast or sero-resistant.
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ular group. No indications of renal irritation were observed.
There were no fatalities.
Clinical observations and therapeutic results
Effect on serology. Therapeutic results, in so far as effect on
serology is concerned, are summarized in Fig. 3. In this figure the
sex and age of each patient, the stage of syphilis, and the result of
dark-field examination ofsyphilitic lesions are recorded. A positive
Kahn plus a positive Wassermann on the blood is represented by
the solidly blocked portion of the horizontal columns, while a posi-
tive Kahn with a negative Wassermann reaction is represented by
the stippled part of the column. The clear zone of the column
_ indicates complete sero-neg-
90 l -NEc ativity. The figures at the
<68 OKAHN-WC.. top and the bottom of the
T 70 graph represent the number
of weeks of follow-up ob-
servation after treatment.
40, The portion of the column 2<0. r just to the left of the ver-
o0 rtical double line shows the
00 _ 4 8 a _ 20 _E 26_state of the serology before
WEEKS AFTER THERAPY treatment. The exponents
FIG. 4. Rate of sero-reversal in those cases (19) attached to some of the
attaining that status. The blocked columns represent
the return of the Wassermann to negative; the clear patients' initials represent
columns represent complete sero-reversal with negative the first or second course of
Kahn and Wassermann reactions. treatment in those partic-
ular patients who, for one reason or another, received re-treatment.
It is obvious then, from this figure, that both the Kahn and
Wassermann reactions were positive before the S-day therapy in all
but one case. In this specific instance (No. 19-0. P.), the Kahn
only was positive before therapy although the Wassermann reaction
also became positive during therapy.
In this group of 33 patients with 36 "treatment courses," 19
patients have had a complete sero-reversal, the remainder of the
group, with the exception of two cases, having been followed for less
than six months after therapy. The rate at which these 19 patients
attained sero-negativity is illustrated in Fig. 4 and, in general, the
trend toward this status is similar to that described by Elliott et al.3
in a much larger group of patients treated with massive arseno-
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therapy. Because of the small number of cases involved, no attempt
has been made in this graph to analyze separately or to make a com-
parison of the ultimate status or the rate of return to sero-negativity
between the primary and secondary cases of syphilis. It is clear,
however, from previous reports on massive arsenotherapy,3' 8 that
both the percentage of cases demonstrating sero-reversal and the
rate at which they attained sero-negativity are highest in the sero-
negative primary group, next in the sero-positive group, and lowest
in the group with evidences of secondary syphilis.
Four of the 33 patients have been lost for further observation.
Of these four patients, two (2-J. Mc. and 10-S. R.) had com-
plete sero-reversals on the 4th and 3rd week, respectively, while
in the remaining two cases, the Wassermann reaction had reverted
to negative by the 9th week though the Kahn test remained positive
at that time, when they were lost for further observation.
Treatment failures. Less than one-half of the group have been
followed for a period of 6 months or longer, although sero-reversal
has taken place already in a number of patients followed for a
shorter period. In that particular group of patients followed for a
period of 6 months or longer, and which number 12 (excluding the
case with reinfection, Case 13-J. M.), there would appear to be
3 failures, namely, cases 8, 12, and 14, although it is still possible
that the last case may have a sero-reversal after 4 or 8 more weeks
of observation. Data on these 3 cases are recorded below.
CASE 8. R. R., a 24-year-old white female, with subsiding secondary
rash of 2 months duration, sero-positive, and an exposure to known syphilitic
source 5 months before admission. Sero-reversal occurred 15 weeks after
therapy, and she was exposed on many occasions to at least 4 different sources
(serologies on sexual partners unknown) for the next 5 months. The Kahn
and Wassermann reactions returned to positive 38 weeks after therapy and
were interpreted as a serological relapse, since no early lesions of syphilis were
discovered during the next 13 weeks of observation. Cerebrospinal fluid nega-
tive. Re-treated with massive arsenotherapy (No. 22-R. R.2), no Herx-
heimer; sero-reversal 10 weeks after second course of therapy. She was sero-
negative at the last check-up 19 weeks after therapy.
CASE 12. M. F., a 28-year-old white female, secondary lesions of 6
weeks duration, sero-positive. Remained sero-positive for 40 weeks, with
fluoroscopy and x-ray of the heart negative, complete physical examination
negative, cerebrospinal fluid negative on 3 occasions (1, 21, and 36 weeks
after therapy) except for a colloidal gold curve of 1244431000. Re-treated
with massive arsenotherapy (No. 30-M. F.2), moderately severe Herx-
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heimer reaction. Cerebrospinal fluid at end of therapy negative (no cells,
Pandy and Wassermann negative, protein 21 mg. per cent) except for col-
loidal gold curve of 4454210000. At 4 weeks after the 2nd course of
therapy the serology remains positive.
CASE 14. A. P., a 21-year-old white female, secondary lesions of 4 weeks
duration, exposure to known syphilitic with penile chancre 6 months before
admission, sero-positive. She remains sero-positive 26 weeks after therapy,
clinically negative for syphilis. Cerebrospinal fluid not examined since the
massive arsenotherapy course was given, at which time it was negative.
Reinfection. One patient (No. 13-J. M.) who had attained
sero-negativity 12 weeks after therapy, became sero-positive on the
18th week. It would appear probable that he was reinfected. The
following case history is related in support of this view.
CASE 13. J. M., a 22-year-old negro male; penile chancre of 3 weeks
duration, dark-field negative (marked secondary infection), sero-positive.
Mild Herxheimer on first day of treatment, secondary fever, course otherwise
uneventful. Cerebrospinal fluid at end of therapy revealed positive Wasser-
mann, colloidal gold curve 1245210000, no cells, Pandy negative. Five
weeks later, cerebrospinal fluid entirely negative. Sero-reversal 12 weeks
after treatment. Epidemiological data subsequent to the time of sero-reversal
is as follows:
12X2 weeks: Intercourse with Contact A.
14 weeks: Contact A admitted to a New York State Hospital with
diagnosis of secondary syphilis. Report of hospital, "Dark-
field positive ulcerations of labia minora and 4+ Wasser-
mann."
19 weeks: Patient J. M. appeared at New Haven Hospital with penile
chancre of 3 weeks duration, dark-field positive, requesting
another course of therapy.
Another course of massive arsenotherapy given (No. 15-J. M.2), une-
ventful except for mild Herxheimer reaction. Cerebrospinal fluid at end of
therapy negative (Wassermann negative, colloidal gold 0000000000, Pandy
negative, 1 lymphocyte and 16 red cells per cu. mm., the latter probably
traumatic in origin). Sero-reversal 8 weeks after second course of treatment,
remains sero-negative at time of last check-up, 22 weeks after second course
of treatment.
Retreated cases. No evidence of sensitivity toward arsenic was
obtained in the 3 patients who received a second course of treatment,
the indications for which are discussed above. Case 8-R. R. vom-
ited 11 times and developed a generalized maculo-papular toxico-
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derma of 24 hours duration at the end of therapy during the first
"treatment course," and during the follow-up period she had mild
paresthesias of the lower extremities. With the second course of
therapy and follow-up period, no toxic symptoms of any type were
observed.
In the case of 12-M. F., there was a mild Herxheimer reac-
tion with minimal vomiting (4 times) during the first day and in the
follow-up period, mild paresthesias developed in the feet. During
the second "treatment course" there was a moderately severe Herx-
heimer reaction with vomiting (5 times) during the first day. No
evidence of peripheral neuritis has developed up to four weeks of
follow-up observation. The third patient, 13-J. M., had, as toxic
manifestations during the first course of therapy, a secondary fever of
102.40 F. on the 5th day and mild paresthesias of the lower extremi-
ties during the follow-up period. With the second course there
was a mild Herxheimer reaction, but no evidence of secondary fever
and no evidence of peripheral neuritis.
Effect of treatment on Tr. pallidum. In a limited number of
cases the data concerning the effect of massive arsenotherapy upon
the Tr. pallidum were obtained and are detailed in Table 7. It is
evident that the dark-field examination in 5 cases (3 primary and 2
secondary lesions) was invariably negative 24 hours after the first
day's dose was started.
TABLE 7
EFFECT OF MASSIVE ARSENOTHERAPY UPON THE Tr. pallidum DURING THE
FIRST DAY OF THERAPY
Typo Dark-field examination
Case lesion Inikl 6 hours* 12 hours* 18 hours* 24 hours*
6-L.F. P + +
15-J. M.2 p II
26-E. P. P ++ ±_
28-S. G. S _
29-V. I. S H _
* Hours after beginning constant intravenous drip on first day of therapy.
Effect of massive arsenotherapy on the cerebrospinal fluid. The
status ofthe cerebrospinal fluid, includingcell count, Pandy, colloidal
gold curve, and Wassermann reaction, was determined in 4 cases at
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some time during the 4th to the 15th week after therapy; and in
another group of 8 cases similar data were obtained at the 16th to
the 35th week. In most instances lumbar puncture was carried out
after therapy and served to establish the initial findings. These
data are recorded in Tables 8 and 9.
In Table 8 it is apparent that Cases 13-J. M. and 16-D. F.
had cerebrospinal fluid findings of a positive nature, including posi-
TABLE 8
CEREBROSPINAL FLUID FOLLOW-UP DATA AT 4TH TO 1 5TH WEEK
Lumbar puncture at 4th to 15th
Initial lumbar puncture* week
Cells Cells
percu. Colloidal percu. Colloidal
Case mm. Pandy WaR** gold curve mm. Pandy WaR** gold curve
13-J. M.1 0 neg. +/+ 1245210000 0 neg. -/- 0000000000
16-D.F. 0 ++ +/+ 5555431100 0 neg. -/- 2455410000
17-A. Fo. 0 neg. -/- 0123210000 0 neg. -/- 0123100000
20-J. Bo. 2 neg. -/- 2233321000 4 neg. -/- 0000000000
* Lumbar puncture one or two days after therapy.
** Numerator of fraction indicates result obtained by performing test with 0.5 cc.
of C. S. F.; denominator indicates result obtained by carrying out test with 0.1 cc.
of C. S. F.
tive Wassermann reactions and abnormal colloidal gold curves, and
in Case 16 a positive Pandy was also present. The follow-up lum-
bar punctures, in Case 13-J. M. on the 5th week and in Case 16
D. F. on the 13th week, were both negative except for an abnormal
colloidal gold curve (2455410000) in the latter patient. The sig-
nificance of this finding, with negative Pandy and Wassermann tests
and in the absence of cellular reaction, is difficult to determine. The
status of the cerebrospinal fluid in the remaining two patients in
Table 8 during the follow-up period, and in all 8 patients in Table 9
in which the lumbar punctures were done at a time between the 16th
and 35th weeks, could be adjudged essentially negative.
In an additional 15 patients a similar study on the cerebrospinal
fluid, together with determination of total protein, was carried out,
although a sufficiient period has not elapsed for follow-up study.
Suffice it to say that except for two instances in which the only abnor-
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mal findings were colloidal gold curves of 1234100000 (Case 21-
M. G.) and 4454210000 (Case 30-M. F.2), the cerebrospinal fluid
was negative. The values for total proteins ranged from 21 to 45
ng. per cent.
TABLE 9
CEREBROSPINAL FLUID FOLLOW-UP DATA AT 16TH TO 35TH WEEK
Lumbar punctuire at 16th to 35th
Initial lumbar puncture* week
Cells Cells
per cu. Colloidal percu. Colloidal
Case mm. Pandy WaR** gold curve mm. Pandy WaR** gold curve
3-I. R. .... .... .......... neg. -/- 0000000000
8-R. R.1 .... .... . °. 0 neg. -/- 0000000000
9-M. M. . ... ...... ....................I neg. -/- 0000000000
II-F. R. 3 neg. -/- 1234210000 3 neg. -/- 0000000000
12-M. F.' 0 neg. /- 0000000000 0 neg. -/- 1233310000
18-F. D. 0 + -/- 0000000000 0 neg. -/- 0000000000
19-O. P. I I (rbc) neg. -/- 0000000000 0 neg. -/- 0000000000
25-G. H. 11 neg. -/ 0000000000 0 neg. -/- 0000000000
* Lumbar puncture one or two days after therapy.
** Numerator of fraction indicates result obtained by performing test with 0.5 cc.
of C. S. F.; denominator indicates result obtained by carrying out test with 0.1 cc.
of C. S. F.
Pregnancy as a complication, and its outcome. Observations upon
the association of pregnancy with massive arsenotherapy have been
afforded in 4 ofthe casestreated. In two instances (Case 21 -M. G.
and Case 33-M. R.), pregnancy was present during the time of
treatment, the duration of pregnancy being S weeks in the first case
and 14 weeks in the second case. The constant-drip therapy was
carried through in both patients without any undue toxic symptoms
or sequelae. The fetus, so far as one can tell by maternal inspec-
tion, has not been affected in any way by the massive arsenotherapy.
Both cases are still in the process of follow-up.
The remaining two patients (Case 1-B. B. and Case 3-I. R.)
became pregnant 8 and 14 weeks, respectively, after treatment, at
351YALE JOURNAL OF BIOLOGY AND MEDICINE
which times their serologies were still positive. These 2 patients
received no further antisyphilitic therapy and both were delivered
of normal, full-term infants. The child of Case 1-B. B. has been
closely followed for 24 weeks and no serological, roentgenographic,
or clinical evidence of syphilis has developed. The child of Case
3-I. R. has been followed in a similar fashion for 26 weeks with
no apparent signs of syphilis developing.
All 4 of these cases are reported in a subsequent paper"5 in full
detail. Case 3-I. R. has been reported as a case of gum
chancre.1"
Discussion
It is obvious that we can draw little or nothing in the way of
conclusions regarding the therapeutic efficacy of this new form of
treatment because of the small number of cases treated and the rela-
tively short follow-up. Suffice it to say, however, that this form
of massive arsenotherapy has been eminently successful in the fol-
lowing respects.
One hundred per cent of patients have completed 100 per cent
of treatment, as compared to the estimated 10 to 20 per cent of
syphilitics who complete a continuous and adequate course of weekly
arsenical injections with the routine conservative procedure. No one
knows what happens to the remaining 80 to 90 per cent, because
many of them never return for follow-up. Of the few who do
return, Paget"0 has shown that the results obtained are no better
than in a group of patients who received no antisyphilitic therapy.
Patients treatedwith massive arsenotherapy do not have to return
week after week for a year and a half, omitting meals before or after
therapy to prevent gastro-intestinal symptoms. They return at
various intervals only for examination of serology and at times for
physical examination. They are admitted to the hospital for a week
or a week and a half, as with any other type of infectious disease,
and when released from isolation they are, in all probability, incap-
able of transmitting syphilis to others.
Concerning specific therapeutic results to the patients themselves,
results would appear to be satisfactory, at least in regard to serology.
In our group of 12 patients followed for 24 weeks or longer, 3 have
been classed as treatment failures, although close inspection of the
case records suggests that in one instance the serology may still
revert to negative and in another instance the possibility of reinfec-
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tion must be considered, thus leaving only one definite case of sero-
resistance, a condition which sometimes follows the best available
treatment.
On the other hand, at present the toxic manifestations of massive
arsenotherapy preclude its general use except in a well-organized
hospital where capable personnel are always available. The reactions
at times are exceedingly trying, witness Case 35, A. Fr. Fortu-
nately, and at least up to this time, we have seen no manifestations
of cerebral irritation. This grave complication has been called
hemorrhagic encephalitis, although postmortem examination in
these cases which have come to autopsy,' has not revealed the char-
acteristic pathological findings of that neurological disease.
The observations of Hyman and his co-workers, together with
our limited studies, certainly demonstrate the low incidence of
syphilis of the central nervous system following this form of
therapy.
Although this form of therapy needs further study in view of
the toxic manifestations, it would appear probable that its develop-
ment to date constitutes a notable advance in the field of syphilo-
therapy. Its field of particular application is clearly indicated in
that group of syphilitics who will not or cannot return week after
week for a year and a half to receive their injections, because it is
especially this group who pass on the disease.
Summary
1. Toxicology, clinical observations, and therapeutic results
obtained with massive arsenotherapy in the treatment of 33 cases
with primary or secondary syphilis by the continuous intravenous-
drip method of Hyman are presented.
2. Females, and particularly pregnant patients, may be treated
in this manner.
3. The toxic manifestations of massive arsenotherapy, previ-
ously described, such as primary and secondary fever, toxicoderma,
jaundice, peripheral neuritis, nausea and vomiting, local thrombo-
phlebitis, and leukopenia were encountered. In addition, the
development of a late secondary anemia and certain electrocardio-
graphic changes, ofa benign and transient nature, in the T waves are
described.
4. Nausea and vomiting are more severe and prolonged in the
female than in the male.
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5. The preliminary administration of a bismuth compound will
not prevent the development of a Herxheimer reaction, at least when
it is given in the manner described in the text.
6. Limited study of the dark-field examination of primary and
secondary lesions suggests that patients are invariably rendered dark-
field-negative within 24 hours.
7. Patients who are re-treated with massive arsenotherapy do
not necessarily acquire anysensitivity to arsenic duringthe first course
of treatment. Indeed, in the case of 3 patients who were re-treated,
toxic reactions seen during the first course of treatment did not neces-
sarily occur with the second course.
8. The rate of return to sero-negative and the number of
patients who attained this status are described.
9. The effect of massive arsenotherapy upon the cerebrospinal
fluid is noted. In 2 instances wherein positive serological findings
were present at the time of treatment, these abnormalities returned
to normal during the follow-up period.
10. In the case of 2 patients who became pregnant within a
four-month period following treatment, no further antisyphilitic
treatment was given. Despite this, both were delivered of normal
full-term infants.
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ADDENDUM
The authors wish to express their indebtedness to the members of the Resident
House Staff for their assistance in carrying out the details of treatment, and to the
various Health Officers of the State of Connecticut for their assistance in referral of
and follow-up observations on patients. Much credit must go to the Nursing Staff
of the New Haven Hospital for their aid, particularly Miss Margaret MacWilliams,
Miss Violet Michaelson, and Miss Mary Wheeler. Mrs. Edna Lyon of the Serology
Laboratory of the Department of Immunology, Yale University School of Medicine.
performed the Kahn and Wassermann reactions described in this report.